Learn About Solitary Fibrous Tumor

What is the definition of Solitary Fibrous Tumor?

Solitary fibrous tumor (SFT) is a noncancerous tumor of the lining of the lung and chest cavity, an area called the pleura. SFT used to be called localized fibrous mesothelioma.

What are the alternative names for Solitary Fibrous Tumor?

Mesothelioma - benign; Mesothelioma - fibrous; Pleural fibroma

What are the causes of Solitary Fibrous Tumor?

The exact cause of SFT remains unknown. This type of tumor affects men and women equally.

What are the symptoms of Solitary Fibrous Tumor?

About one half of the people with this type of tumor do not show any symptoms.

If the tumor grows to a large size and pushes on the lung, it can lead to symptoms, such as:

  • Chest pain
  • Chronic cough
  • Shortness of breath
  • Clubbed appearance of the fingers
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Solitary Fibrous Tumor?

SFT is usually treated by removing the tumor.

Who are the top Solitary Fibrous Tumor Local Doctors?
Mina K. Sinacori
Advanced in Solitary Fibrous Tumor
Obstetrics and Gynecology
Advanced in Solitary Fibrous Tumor
Obstetrics and Gynecology

Texas Health Womens Care

6300 W Parker Rd, Ste 126, 
Plano, TX 
Languages Spoken:
English, Spanish

Dr. Mina K. Sinacori was born and raised in suburban Long Island, N.Y. She graduated with her medical degree from New York University School of Medicine, and also earned a Master of Public Health degree while at NYU. She is a board-certified obstetrician and gynecologist.Dr. Sinacori married her college sweetheart and relocated to Houston, Texas, where she completed her OB/GYN residency at Baylor College of Medicine. Prior to joining Texas Health Women's Care, she served as the lead physician in a private practice in the Houston area. Her clinical interests include normal and high-risk pregnancy, contraception, menstrual disorders, breast health, cervical dysplasia, fibroids, robotic/minimally invasive surgery, hormonal therapy, treatment for sexually transmitted infections, and preventative women's healthcare. Her goal is delivering individualized and compassionate care for women of all ages.Dr. Sinacori has served on multiple executive boards and committees involved in patient advocacy and quality care initiatives. She was 2021 President of the Houston Academy of Medicine, 2022-24 Chair of the Texas Medical Association's Council on Health Service Organizations, and 2023 President of Harris County Medical Society, the largest county medical society in the country. She has published research on innovative technologies in maternal-fetal medicine and spoken on many topics including wellness, contraception, public health, and HPV vaccination/virology. Dr. Sinacori believes in the benefits of preventive care and healthy living during pregnancy and throughout life. She is passionate about personalizing her patient care around each woman's unique needs for health and wellness.Dr. Sinacori is a Diplomate of the American Board of Obstetrics & Gynecology and a Fellow of the American College of Obstetricians and Gynecologists. She and her husband have two wonderful children and a close-knit family. She loves animals, cooking, and enjoys the outdoors. Dr. Sinacori is rated as an Advanced provider by MediFind in the treatment of Solitary Fibrous Tumor. Her top areas of expertise are Carney Complex, Solitary Fibrous Tumor, Intestinal Leiomyoma, Female Genital Sores, and Intrauterine Device Insertion.

Manisha S. Parikh
Advanced in Solitary Fibrous Tumor
Obstetrics and Gynecology
Advanced in Solitary Fibrous Tumor
Obstetrics and Gynecology

Texas Health Womens Care

1615 Hospital Pkwy, Ste 300, 
Bedford, TX 
Languages Spoken:
English

Dr. Manisha Parikh has served the health care needs of women in the DFW area since 2006. In addition to her practice, she has served as vice chair of the Obstetrics and Gynecology department at Texas Health HEB since 2021. She is also an assistant professor at Texas Christian University and the University of North Texas Health Science Center School of Medicine in Fort Worth. Dr. Parikh is board-certified in obstetrics and gynecology and holds certification in the da Vinci robotic surgical system. Her clinical interests include adolescent gynecology; minimally invasive and hysteroscopic surgical procedures; and the diagnosis and treatment of pelvic organ prolapse, polycystic ovarian syndrome (PCOS), ectopic pregnancy and hormone imbalance. Dr. Parikh earned her medical degree at Medical College of Georgia in Augusta. She completed her obstetrics and gynecology residency at Baylor College of Medicine in Houston, serving as chief resident in her final year. Dr. Parikh is a Diplomate of the American Board of Obstetrics and Gynecology and a Fellow of the American College of Obstetricians and Gynecologists. She is a member of the Texas Medical Association and Tarrant County Medical Society. Dr. Parikh has been recognized numerous times as a Top Doc by Fort Worth Magazine and Southlake Magazine and as a Mom Approved Doctor by Fort Worth Child Magazine. Dr. Parikh is rated as an Advanced provider by MediFind in the treatment of Solitary Fibrous Tumor. Her top areas of expertise are Carney Complex, Solitary Fibrous Tumor, Intestinal Leiomyoma, Intrauterine Device Insertion, and Hormone Replacement Therapy (HRT).

 
 
 
 
Learn about our expert tiers
Learn More
Tina L. Thai
Advanced in Solitary Fibrous Tumor
Obstetrics and Gynecology
Advanced in Solitary Fibrous Tumor
Obstetrics and Gynecology

Texas Health Womens Care

6300 W Parker Rd, Ste 126, 
Plano, TX 
Languages Spoken:
English

Dr. Tina Thai was born and raised in Texas, spending much of her early years in the Austin area before starting her undergraduate studies in Killeen, Texas. She later earned her medical degree at the University of North Texas Health Science Center - Texas College of Osteopathic Medicine in Fort Worth. She completed her Ob/Gyn residency at Texas Tech University Health Science Center Permian Basin in Odessa, where she was chief resident in her final year of training. Dr. Thai has served the women’s care needs of the Plano community since 2021. She evaluates and manages a broad range of obstetrical and gynecological concerns and is skilled in minimally invasive surgical techniques, including robotic-assisted surgeries. Dr. Thai is a member of the American Congress of Obstetricians & Gynecologists and American Medical Association. When not with her patients, she enjoys spending time with her husband and fur baby, Buddy, playing tennis, and doing arts and crafts projects. Dr. Thai is a Fellow of the American College of Obstetricians and Gynecologists. She is also a member of the American Congress of Obstetricians & Gynecologists and American Medical Association. Dr. Thai is rated as an Advanced provider by MediFind in the treatment of Solitary Fibrous Tumor. Her top areas of expertise are Solitary Fibrous Tumor, Carney Complex, Intestinal Leiomyoma, Hormone Replacement Therapy (HRT), and Salpingo-Oophorectomy.

What is the outlook (prognosis) for Solitary Fibrous Tumor?

The outcome is expected to be good with prompt treatment. In rare cases, the tumor may return.

What are the possible complications of Solitary Fibrous Tumor?

Fluid escaping into the membranes around the lungs (pleural effusion) is a complication.

When should I contact a medical professional for Solitary Fibrous Tumor?

Contact your provider for an appointment if you notice symptoms of SFT.

What are the latest Solitary Fibrous Tumor Clinical Trials?
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Summary: This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

Summary: Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (...

Who are the sources who wrote this article ?

Published Date: August 19, 2024
Published By: Allen J. Blaivas, DO, Division of Pulmonary, Critical Care, and Sleep Medicine, VA New Jersey Health Care System, Clinical Assistant Professor, Rutgers New Jersey Medical School, East Orange, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

Kaidar-Person O, Zagar T, Haithcock BE, Weiss, J. Diseases of the pleura and mediastinum. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 70.

Konopka K, Arenberg DA. Benign lung tumors. In: Broaddus VC, Ernst JD, King Jr TE, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 7th ed. Philadelphia, PA: Elsevier; 2022:chap 80.